Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

RENOQUID

SULFACYTINE

Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview RENOQUID is listed in Drugs@FDA under application 017569 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient SULFACYTINE Form and strength TABLET;ORAL - 250MG Sponsor GLENWOOD Submission history Latest submission status date: 1986-12-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview RENOQUID is listed in Drugs@FDA under application 017569 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient SULFACYTINE Form and strength TABLET;ORAL - 250MG Sponsor GLENWOOD Submission history Latest submission status date: 1986-12-16 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Discontinued
  • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.
RENOQUID (SULFACYTINE) | Drug Monograph | MedicHelpline